Galderma Announces Positive Results from their Phase 3 Study of RelabotulinumtoxinA

In a recent press release, Galderma announced that RelabotulinumtoxinA significantly improved glabellar and lateral canthal lines.


Data from their Phase III READY-3 clinical trial reveal that a single dose of RelabotulinumtoxinA improved both frown lines and crow’s feet when treated alone or simultaneously with a long-duration effect of six months.

The study includes over 1900 participants taking part in a double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of RelabotulinumtoxinA as measured by aesthetic improvement in patients with moderate to severe frown lines or crow’s feet. Treatment was administered as a single-area treatment or simultaneously on both frown lines and crow’s feet and compared to placebo.

Researchers reveal that the study met its co-primary endpoints. Both patients and investigators reported at least a two-grade improvement in line severity at one month. For single-area treatment, it was measured at 71% for frown lines and 45% for crow’s feet, and simultaneous treatment, at 72% for frown lines and 55% for crow’s feet when compared to placebo.

The median time of return to baseline line severity as measured by both investigator and patient was approximately six months – 24-25 weeks for single-area treatment and 25-27 weeks for simultaneous treatment. The study also reported high satisfaction levels among patients, with up to 91% reporting satisfaction with simultaneous treatment at one month.

RelabotulinumtoxinA was well tolerated by patients, with low rates of treatment-related adverse events reported and no serious treatment-related adverse events.

The results of this study further reinforce those of the READY-1 and READY-2 trials demonstrating the safety and efficacy of RelabotulinumtoxinA.

“Patients often want their aesthetic look to last longer or to receive treatment on multiple facial areas simultaneously, and practitioners want to deliver consistent results for their patients. These new data highlight the ability of RelabotulinumtoxinA to address all these key needs for frown lines and crow’s feet, while also being a ready-to-use formulation that’s easy to administer.”


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.